Carbonyl Reductase

Carbonyl reductase

Carbonyl reductase, an NADPH-dependent oxidoreductase, catalyzes the reduction of aldehydes and ketones to primary and secondary alcohols, respectively. This enzyme exhibits broad substrate specificity for various endogenous and xenobiotic carbonyl compounds, facilitating the reduction of endogenous prostaglandins, steroids, and other aliphatic aldehydes and ketones. Carbonyl reductases belong to the short-chain dehydrogenases/reductases (SDR) family. Among them, CBR1 plays a crucial role in protecting cells from oxidative stress-induced damage and is extensively studied for its involvement in drug metabolism, particularly in converting the chemotherapeutic agent Doxorubicin into the cardiotoxic metabolite Danurubicin. Additionally, CBR3, a target gene of the Nrf2 transcription factor, is implicated in inflammatory responses^[1]^[2]^[3].

References:

[1]. Morgan RA, et al. Carbonyl reductase 1 catalyzes 20β-reduction of glucocorticoids, modulating receptor activation and metabolic complications of obesity. Sci Rep. 2017 Sep 6;7(1):10633. [Content Brief]

[2]. Yun M, et al. Carbonyl reductase 1 is a new target to improve the effect of radiotherapy on head and neck squamous cell carcinoma. J Exp Clin Cancer Res. 2018 Oct 30;37(1):264. [Content Brief]

[3]. Malátková P, et al. Expression of human carbonyl reductase 3 (CBR3; SDR21C2) is inducible by pro-inflammatory stimuli. Biochem Biophys Res Commun. 2012 Apr 6;420(2):368-73. [Content Brief]

Carbonyl Reductase Inhibitor (1)

Carbonyl Reductase Related Products (1):

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-155587

Hydroxy-PP	Inhibitor	99.66%
Hydroxy-PP is a potent carbonyl reductase 1 (CBR1) inhibitor with an IC₅₀ value of 0.78 μM. Hydroxy-PP also potently inhibits the cytoplasmic tyrosine kinase Fyn with an IC₅₀ value of 5 nM.

Name
Email *

	Sorry, but the email address you supplied was invalid.